You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesvenlafaxine
Accession NumberDB06700
TypeSmall Molecule
GroupsApproved
DescriptionDesvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.
Structure
Thumb
Synonyms
Desvenlafaxine
O-desmethylvenlafaxine
ODV
Pristiq
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desvenlafaxinetablet, extended release50 mg/1oralSun Pharma Global FZE2014-01-30Not applicableUs
Desvenlafaxinetablet, extended release100 mg/1oralSun Pharma Global FZE2014-01-30Not applicableUs
Desvenlafaxinetablet, extended release50 mg/1oralRanbaxy Pharmaceuticals Inc.2013-03-05Not applicableUs
Desvenlafaxinetablet, extended release100 mg/1oralRanbaxy Pharmaceuticals Inc.2013-03-05Not applicableUs
Desvenlafaxine Extended-releasetablet, extended release100 mg/1oralMacoven Pharmaceuticals2013-07-10Not applicableUs
Desvenlafaxine Extended-releasetablet, extended release50 mg/1oralMacoven Pharmaceuticals2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release50 mg/1oralPernix Therapeutics2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release50 mg/1oralPar Pharmaceutical Inc.2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release100 mg/1oralPernix Therapeutics2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release100 mg/1oralPar Pharmaceutical Inc.2013-07-10Not applicableUs
Pristiqtablet (extended-release)50 mgoralPfizer Canada Inc2009-03-05Not applicableCanada
Pristiqtablet (extended-release)100 mgoralPfizer Canada Inc2009-03-06Not applicableCanada
Pristiq Extended Releasetablet, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-26Not applicableUs
Pristiq Extended-releasetablet, extended release25 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2015-04-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralCardinal Health2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release100 mg/1oralCardinal Health2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release100 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralPhysicians Total Care, Inc.2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
Pristiq Extended-release Extended-releasetablet, extended release50 mg/1oralPd Rx Pharmaceuticals, Inc.2008-05-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desvenlafaxinetablet, extended release50 mg/1oralBreckenridge Pharmaceutical, Inc2015-07-13Not applicableUs
Desvenlafaxinetablet, extended release100 mg/1oralBreckenridge Pharmaceutical, Inc2015-07-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Zyven-OD Not Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Desvenlafaxine fumarate
93414-04-1
Thumb
  • InChI Key: SQTJDJZCPOSWSC-WLHGVMLRSA-N
  • Monoisotopic Mass: 379.199487658
  • Average Mass: 379.453
DBSALT001322
Desvenlafaxine fumarate monohydrate
313471-75-9
Thumb
  • InChI Key: YETWCSLOYUZBLK-JITBQSAISA-N
  • Monoisotopic Mass: 397.210052342
  • Average Mass: 397.468
DBSALT001893
Desvenlafaxine succinate
Thumb
  • InChI Key: ORUUBRMVQCKYHB-UHFFFAOYNA-N
  • Monoisotopic Mass: 381.215137729
  • Average Mass: 381.4632
DBSALT000045
Categories
UNIING99554ANW
CAS number93413-62-8
WeightAverage: 263.3752
Monoisotopic: 263.188529049
Chemical FormulaC16H25NO2
InChI KeyInChIKey=KYYIDSXMWOZKMP-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
IUPAC Name
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
SMILES
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationDesvenlafaxine is indicated for the treatment of major depressive disorder in adults.
PharmacodynamicsDesvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose. Some of the limitations of desvenlafaxine include moderate efficacy in the treatment of major depressive disorder, similar safety and tolerability profile to other SNRIs and possible transient discontinuation symptoms upon cessation of therapy.
Mechanism of actionDesvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.
Related Articles
AbsorptionAbsolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.
Volume of distribution

3.4 L/kg, distribution into nonvascular compartments

Protein binding~ 30%, protein binding is independent of drug concentration.
Metabolism

The primary route of metabolism is via conjugation mediated by UGT isoforms. Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.

SubstrateEnzymesProduct
Desvenlafaxine
N,O-DidesmethylvenlafaxineDetails
Route of eliminationExcreted in the urine. Approximately 45% of the total oral dose is excreted unchanged in urine. Approximately 19% of the total oral dose is excreted as the glucuronide metabolite and < 5% is excreted as the oxidative metabolite, N,O-didesmethylvenlafaxine. Excreted in human milk.
Half lifeThe mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.
ClearanceNot Available
ToxicityThe safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Venlafaxine Metabolism PathwayDrug metabolismSMP00636
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.7722
Caco-2 permeable+0.8404
P-glycoprotein substrateSubstrate0.6918
P-glycoprotein inhibitor INon-inhibitor0.7835
P-glycoprotein inhibitor IIInhibitor0.5921
Renal organic cation transporterNon-inhibitor0.5894
CYP450 2C9 substrateNon-substrate0.7837
CYP450 2D6 substrateSubstrate0.7753
CYP450 3A4 substrateSubstrate0.6997
CYP450 1A2 substrateNon-inhibitor0.6816
CYP450 2C9 inhibitorNon-inhibitor0.757
CYP450 2D6 inhibitorInhibitor0.6334
CYP450 2C19 inhibitorNon-inhibitor0.7811
CYP450 3A4 inhibitorNon-inhibitor0.8646
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8888
Ames testNon AMES toxic0.8084
CarcinogenicityNon-carcinogens0.7648
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.4429 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6046
hERG inhibition (predictor II)Inhibitor0.5603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet (extended-release)oral100 mg
Tablet (extended-release)oral50 mg
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral25 mg/1
Tablet, extended releaseoral50 mg/1
Prices
Unit descriptionCostUnit
Pristiq 100 mg extended-release tablet4.46USD tablet
Pristiq 50 mg extended-release tablet4.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2436668 No2009-05-262022-02-11Canada
US6673838 No2002-03-012022-03-01Us
US8269040 No2007-07-052027-07-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble FDA label
logP0.21FDA label
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP2.6ALOGPS
logP2.29ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.54 m3·mol-1ChemAxon
Polarizability30.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Karel Pospisilik, Lambertus Thijs, “Process for making desvenlafaxine.” U.S. Patent US20070299283, issued December 27, 2007.

US20070299283
General References
  1. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [PubMed:20926994 ]
  2. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  3. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [PubMed:20797382 ]
  4. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  5. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  6. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. doi: 10.1097/YIC.0b013e32832fbb5a. [PubMed:19779354 ]
  7. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. [PubMed:19629022 ]
  8. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. [PubMed:19127490 ]
  9. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
  10. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
  11. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. [PubMed:19142106 ]
  12. Link [Link]
External Links
ATC CodesN06AX23
AHFS Codes
  • 28:16.04.16
PDB EntriesNot Available
FDA labelDownload (379 KB)
MSDSDownload (86.1 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineDesvenlafaxine may decrease the antihypertensive activities of 4-Methoxyamphetamine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Desvenlafaxine.
AcenocoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acetophenazine.
Acetylsalicylic acidDesvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.
AgmatineDesvenlafaxine may decrease the antihypertensive activities of Agmatine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desvenlafaxine.
AmiodaroneThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desvenlafaxine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desvenlafaxine.
AmperozideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amperozide.
ApomorphineDesvenlafaxine may decrease the antihypertensive activities of Apomorphine.
AprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aripiprazole.
AsenapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Asenapine.
AtazanavirThe metabolism of Desvenlafaxine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Desvenlafaxine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Azaperone.
BenmoxinBenmoxin may increase the serotonergic activities of Desvenlafaxine.
BenzphetamineDesvenlafaxine may decrease the antihypertensive activities of Benzphetamine.
BethanidineDesvenlafaxine may decrease the antihypertensive activities of Bethanidine.
BexaroteneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Bifeprunox.
BoceprevirThe metabolism of Desvenlafaxine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Desvenlafaxine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brexpiprazole.
BrimonidineDesvenlafaxine may decrease the antihypertensive activities of Brimonidine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.
BromocriptineDesvenlafaxine may decrease the antihypertensive activities of Bromocriptine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desvenlafaxine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desvenlafaxine.
CarbamazepineThe metabolism of Desvenlafaxine can be increased when combined with Carbamazepine.
CariprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Cariprazine.
CaroxazoneCaroxazone may increase the serotonergic activities of Desvenlafaxine.
CeritinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Ceritinib.
ChlorpromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorprothixene.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Desvenlafaxine.
ClarithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Desvenlafaxine can be decreased when combined with Clemastine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desvenlafaxine.
ClonidineDesvenlafaxine may decrease the antihypertensive activities of Clonidine.
ClotrimazoleThe metabolism of Desvenlafaxine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Clozapine.
CobicistatThe metabolism of Desvenlafaxine can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Desvenlafaxine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Desvenlafaxine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Cyamemazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.
CyclosporineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.
DapiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.
DarunavirThe metabolism of Desvenlafaxine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Desvenlafaxine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Desvenlafaxine can be decreased when combined with Delavirdine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dexamethasone.
DexmedetomidineDesvenlafaxine may decrease the antihypertensive activities of Dexmedetomidine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Desvenlafaxine.
DicoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dicoumarol.
DihydroergotamineThe metabolism of Desvenlafaxine can be decreased when combined with Dihydroergotamine.
DihydroergotamineDesvenlafaxine may decrease the antihypertensive activities of Dihydroergotamine.
DiltiazemThe metabolism of Desvenlafaxine can be decreased when combined with Diltiazem.
DipivefrinDesvenlafaxine may decrease the antihypertensive activities of Dipivefrin.
DolasetronDolasetron may increase the serotonergic activities of Desvenlafaxine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.
DoxycyclineThe metabolism of Desvenlafaxine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Desvenlafaxine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Droperidol.
DroxidopaDesvenlafaxine may decrease the antihypertensive activities of Droxidopa.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.
EfavirenzThe serum concentration of Desvenlafaxine can be decreased when it is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desvenlafaxine.
EnzalutamideThe serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.
EphedraDesvenlafaxine may decrease the antihypertensive activities of Ephedra.
EpinephrineDesvenlafaxine may decrease the antihypertensive activities of Epinephrine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Desvenlafaxine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Desvenlafaxine.
ErgotamineDesvenlafaxine may decrease the antihypertensive activities of Ergotamine.
ErythromycinThe metabolism of Desvenlafaxine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desvenlafaxine.
Eslicarbazepine acetateThe serum concentration of Desvenlafaxine can be decreased when it is combined with Eslicarbazepine acetate.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desvenlafaxine.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.
EtomidateDesvenlafaxine may decrease the antihypertensive activities of Etomidate.
EtravirineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Etravirine.
FencamfamineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desvenlafaxine.
FluconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desvenlafaxine.
FlupentixolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluspirilene.
FluvoxamineThe metabolism of Desvenlafaxine can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluvoxamine.
FosamprenavirThe metabolism of Desvenlafaxine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Desvenlafaxine can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Desvenlafaxine.
FurazolidoneFurazolidone may increase the serotonergic activities of Desvenlafaxine.
Fusidic AcidThe serum concentration of Desvenlafaxine can be increased when it is combined with Fusidic Acid.
GranisetronGranisetron may increase the serotonergic activities of Desvenlafaxine.
GuanabenzDesvenlafaxine may decrease the antihypertensive activities of Guanabenz.
GuanfacineDesvenlafaxine may decrease the antihypertensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.
HydracarbazineHydracarbazine may increase the serotonergic activities of Desvenlafaxine.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Desvenlafaxine.
IdelalisibThe serum concentration of Desvenlafaxine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iloperidone.
ImatinibThe metabolism of Desvenlafaxine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desvenlafaxine.
IndinavirThe metabolism of Desvenlafaxine can be decreased when combined with Indinavir.
Ioflupane I-123Desvenlafaxine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Desvenlafaxine.
IproniazidIproniazid may increase the serotonergic activities of Desvenlafaxine.
IsavuconazoniumThe metabolism of Desvenlafaxine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Isocarboxazid.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Desvenlafaxine.
IsradipineThe metabolism of Desvenlafaxine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Desvenlafaxine can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Ketoconazole.
LevomilnacipranThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Levomilnacipran.
LinezolidLinezolid may increase the serotonergic activities of Desvenlafaxine.
LinezolidThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Linezolid.
LithiumThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lithium.
LofexidineDesvenlafaxine may decrease the antihypertensive activities of Lofexidine.
LopinavirThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Desvenlafaxine.
LovastatinThe metabolism of Desvenlafaxine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Loxapine.
LuliconazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lurasidone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.
MebanazineMebanazine may increase the serotonergic activities of Desvenlafaxine.
MelperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Melperone.
MesoridazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mesoridazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desvenlafaxine.
MethamphetamineDesvenlafaxine may decrease the antihypertensive activities of Methamphetamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Methotrimeprazine.
Methylene blueDesvenlafaxine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Metoclopramide.
MifepristoneThe metabolism of Desvenlafaxine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Desvenlafaxine.
MinaprineMinaprine may increase the serotonergic activities of Desvenlafaxine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desvenlafaxine.
MitotaneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Moclobemide.
MoclobemideMoclobemide may increase the serotonergic activities of Desvenlafaxine.
ModafinilThe serum concentration of Desvenlafaxine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Molindone.
NafcillinThe serum concentration of Desvenlafaxine can be decreased when it is combined with Nafcillin.
NaphazolineDesvenlafaxine may decrease the antihypertensive activities of Naphazoline.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Desvenlafaxine.
NefazodoneThe metabolism of Desvenlafaxine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Nefazodone.
NelfinavirThe metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Desvenlafaxine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Desvenlafaxine.
NilotinibThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Desvenlafaxine.
NorepinephrineDesvenlafaxine may decrease the antihypertensive activities of Norepinephrine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desvenlafaxine.
OctamoxinOctamoxin may increase the serotonergic activities of Desvenlafaxine.
OlanzapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Olanzapine.
OlaparibThe metabolism of Desvenlafaxine can be decreased when combined with Olaparib.
OndansetronThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Desvenlafaxine.
OsanetantThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Osanetant.
OsimertinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Osimertinib.
OxymetazolineDesvenlafaxine may decrease the antihypertensive activities of Oxymetazoline.
PalbociclibThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Desvenlafaxine.
PargylinePargyline may increase the serotonergic activities of Desvenlafaxine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.
PentobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Pentobarbital.
PergolideDesvenlafaxine may decrease the antihypertensive activities of Pergolide.
PerospironeThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desvenlafaxine.
PhenelzineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenelzine.
PhenelzinePhenelzine may increase the serotonergic activities of Desvenlafaxine.
PhenindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Desvenlafaxine.
PhenobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Desvenlafaxine.
PhenprocoumonThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenprocoumon.
PhenylpropanolamineDesvenlafaxine may decrease the antihypertensive activities of Phenylpropanolamine.
PhenytoinThe metabolism of Desvenlafaxine can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipotiazine.
PirlindolePirlindole may increase the serotonergic activities of Desvenlafaxine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Desvenlafaxine.
PosaconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Posaconazole.
PrimidoneThe metabolism of Desvenlafaxine can be increased when combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Desvenlafaxine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desvenlafaxine.
PropericiazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Propericiazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.
PseudoephedrineDesvenlafaxine may decrease the antihypertensive activities of Pseudoephedrine.
QuetiapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Quetiapine.
RanolazineThe metabolism of Desvenlafaxine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Rasagiline.
RasagilineRasagiline may increase the serotonergic activities of Desvenlafaxine.
RemoxiprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Reserpine.
RifabutinThe metabolism of Desvenlafaxine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Desvenlafaxine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Desvenlafaxine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Risperidone.
RitonavirThe metabolism of Desvenlafaxine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Desvenlafaxine.
RopiniroleDesvenlafaxine may decrease the antihypertensive activities of Ropinirole.
SafrazineSafrazine may increase the serotonergic activities of Desvenlafaxine.
SaquinavirThe metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.
SelegilineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Selegiline.
SelegilineSelegiline may increase the serotonergic activities of Desvenlafaxine.
SertindoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desvenlafaxine.
SildenafilThe metabolism of Desvenlafaxine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Desvenlafaxine can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Desvenlafaxine can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe serum concentration of Desvenlafaxine can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Desvenlafaxine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Desvenlafaxine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desvenlafaxine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Desvenlafaxine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tedizolid Phosphate.
TelaprevirThe metabolism of Desvenlafaxine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Telithromycin.
ThioproperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiothixene.
TiclopidineThe metabolism of Desvenlafaxine can be decreased when combined with Ticlopidine.
TizanidineDesvenlafaxine may decrease the antihypertensive activities of Tizanidine.
TocilizumabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.
ToloxatoneToloxatone may increase the serotonergic activities of Desvenlafaxine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desvenlafaxine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Desvenlafaxine.
TranylcypromineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tranylcypromine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Desvenlafaxine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desvenlafaxine.
VenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Venlafaxine.
VerapamilThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desvenlafaxine.
VoriconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Vortioxetine.
WarfarinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Warfarin.
XylometazolineDesvenlafaxine may decrease the antihypertensive activities of Xylometazoline.
ZiprasidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desvenlafaxine.
ZotepineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
Comments
comments powered by Disqus
Drug created on May 06, 2010 10:22 / Updated on September 30, 2016 02:25